UPDATE: Jefferies Starts Nuvation Bio Inc (NUVB) at Buy

March 8, 2021 4:32 AM EST
Get Alerts NUVB Hot Sheet
Price: $11.35 -3.49%

Rating Summary:
    5 Buy, 0 Hold, 0 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 17 | Down: 13 | New: 41
Trade Now! 
Join SI Premium – FREE
(Updated - March 8, 2021 7:43 AM EST)

Jefferies analyst Michael Yee initiates coverage on Nuvation Bio Inc (NYSE: NUVB) with a Buy rating and a price target of $20.00.

The analyst commented, "We initiate NUVB at BUY based on a deep pipeline of targeted oncology programs in blockbuster markets, strong and proven mgmt, and a strong balance sheet that supports many readouts over the next few years w/ little need for capital. The co has elegant chemistry in multiple high-value cancer areas including CDK2/4/6, BET, WEE1, and very intriguing "PARP drug conjugate" program which is a unique and valuable platform against prostate and breast cancer."

For an analyst ratings summary and ratings history on Nuvation Bio Inc click here. For more ratings news on Nuvation Bio Inc click here.

Shares of Nuvation Bio Inc closed at $10.86 yesterday.


You May Also Be Interested In





Related Categories

Analyst Comments, New Coverage

Related Entities

Jefferies & Co